This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Extended Release Naltrexone for Treating Amphetamine Dependence in Iceland

This study has been completed.
Sponsor:
Collaborators:
National Institute on Drug Abuse (NIDA)
Society of Alcoholism and other Addictions
Information provided by (Responsible Party):
Helen Pettinati, National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:
NCT01100853
First received: April 7, 2010
Last updated: November 25, 2013
Last verified: November 2013
Results First Received: July 9, 2013  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: None (Open Label);   Primary Purpose: Treatment
Condition: Amphetamine Dependence
Intervention: Drug: VIVITROL injection and VIVITROL Placebo Injection , 24 weeks

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
VIVITROL Injection, 24 Weeks Efficacy of 24 week course of VIVITROL with counseling as compared to 24 week course of VIVITROL placebo with counseling (monthly injections)
VIVITROL Placebo Injection, 24 Weeks Efficacy of 24 week course of VIVITROL with counseling as compared to 24 week course of VIVITROL placebo with counseling (monthly injections)

Participant Flow:   Overall Study
    VIVITROL Injection, 24 Weeks   VIVITROL Placebo Injection, 24 Weeks
STARTED   51   49 
COMPLETED   24   26 
NOT COMPLETED   27   23 
Lost to Follow-up                11                6 
Received <4 study injections                10                13 
Withdrawal by Subject                6                4 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
VIVITROL Injection, 24 Weeks Efficacy of 24 week course of VIVITROL with counseling as compared to 24 week course of VIVITROL placebo with counseling (monthly injections)
VIVITROL Placebo Injection, 24 Weeks Efficacy of 24 week course of VIVITROL with counseling as compared to 24 week course of VIVITROL placebo with counseling (monthly injections)
Total Total of all reporting groups

Baseline Measures
   VIVITROL Injection, 24 Weeks   VIVITROL Placebo Injection, 24 Weeks   Total 
Overall Participants Analyzed 
[Units: Participants]
 51   49   100 
Age 
[Units: Participants]
     
<=18 years   0   0   0 
Between 18 and 65 years   51   49   100 
>=65 years   0   0   0 
Age 
[Units: Years]
Mean (Standard Deviation)
 31.51  (1.11)   31.59  (1.34)   31.55  (1) 
Gender 
[Units: Participants]
     
Female   15   10   25 
Male   36   39   75 
Region of Enrollment 
[Units: Participants]
     
Iceland   51   49   100 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Number Negative Urines (Proportion Negative Urines)   [ Time Frame: 24 Weeks ]

2.  Primary:   Number Negative Urines (Proportion Negative Urines) Amphetamine   [ Time Frame: 24 weeks ]

3.  Secondary:   Amphetamine Craving Scale   [ Time Frame: 24 weeks ]

4.  Secondary:   Beck Depression Inventory   [ Time Frame: 24 weeks ]

5.  Secondary:   Risk Assessment Battery   [ Time Frame: 24 weeks ]

6.  Secondary:   Prior Admissions to Vogur Hospital   [ Time Frame: Baseline ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Dr. Helen Pettinati
Organization: University of Pennsylvania
phone: 215-222-3200 ext 139
e-mail: helenp@mail.med.upenn.edu



Responsible Party: Helen Pettinati, National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier: NCT01100853     History of Changes
Other Study ID Numbers: 811095
P50DA012756 ( U.S. NIH Grant/Contract )
2009-013647-10 ( EudraCT Number )
Study First Received: April 7, 2010
Results First Received: July 9, 2013
Last Updated: November 25, 2013